All In Biotech

Investigational drug · Phase 3

DP303c

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-positive Breast Cancer, Advanced Solid Tumors, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

9

Any phase or sponsor naming "DP303c"

First trial start

2023

Jul 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "DP303c", any sponsor or status.

Conditions studied

As listed on its trial records.

  • HER2-positive Breast Cancer
  • Advanced Solid Tumors
  • Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
  • Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)
  • Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
  • HER2-positive Advanced Breast Cancer

Approved drugs for the same conditions: Breast cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "DP303c" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for HER2-positive Breast Cancer

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • TQB2102Phase 311 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors

  • DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials

    DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer

  • IBI354Phase 33 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal

  • A166Phase 32 trials

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Her 2 Positive Breast Cancer, HER2-positive Breast Cancer

  • ZN-A-1041ZN-A-1041 Enteric, RO7771950Phase 32 trials

    Roche (Genentech) · HER2-positive Breast Cancer, Advanced Solid Tumors

  • GQ1005Phase 31 trial

    GeneQuantum Healthcare (Suzhou) Co., Ltd. · HER2-positive Breast Cancer

  • HLX11Phase 31 trial

    Shanghai Henlius Biotech · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.